Catalyst
Slingshot members are tracking this event:
Phase 3 final endpoint of NeuVax (E75) for low-to-intermediate HER2+ breast cancer is expected to be reached in 2018 - Terminated
Do you think this event is important to the companies below? How will it affect their stock price?
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 01, 2018
Occurred Source:
https://www.sellaslifesciences.com/investors/news/News-Details/2018/SELLAS-Life-Sciences-Provides-Clinical-Update-on-Phase-2b-NeuVax-nelipepimut-S-Study-in-Combination-with-Trastuzumab-in-HER2-12-Breast-Cancer-Patients/default.aspx
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Endpoint, Neuvax, E75, Low-to-intermediate Her2+ Breast Cancer, Terminated, Discontinued, Discontinuation
